ArticleScientific reports2026
Electrospun polyurethane-eggshell membrane hybrid nanofibrous scaffolds for enhanced fibroblast adhesion and growth in skin tissue engineering.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic wounds demand scaffolds that simultaneously deliver mechanical resilience and biological cues to restore fibroblast function and extracellular matrix remodeling. However, it remains unknown how polyurethane–eggshell membrane (PU–ESM) composition quantitatively governs the trade-off between mechanics, physicochemical behavior, and fibroblast responses. Here we establish composition–function relationships in electrospun PU–ESM nanofibrous scaffolds to resolve the optimal balance for skin tissue engineering. Electrospun PU, native and extracted ESM variants, and PU/ESM hybrids (90:10, 80:20, 70:30) were fabricated and evaluated by SEM/EDX/ATR-FTIR, wettability, swelling, degradation, tensile testing, and fibroblast assays (MTT and SEM adhesion; n = 3). ESM incorporation progressively increased hydrophilicity, swelling, and degradation while tuning mechanics (all ANOVA P < 0.001). The 80:20 hybrid achieved a contact angle of 81.56 ± 2.74°, controlled swelling, and intermediate degradation, with stiffness 17.36 ± 0.72 MPa and tensile strength 3.96 ± 0.21 MPa. Fibroblast viability on 80:20 matched controls (P > 0.05) and exceeded pure ESM scaffolds (P < 0.01). SEM quantification revealed previously unresolved gains in cell–scaffold interaction at 80:20, with ~ 2.25-fold higher cell density and ~ 3.8-fold greater cell-covered area versus ePU (P < 0.0001), alongside enhanced spreading. These data demonstrate that a defined PU–ESM ratio (80:20) provides a previously inaccessible balance of mechanics and bioactivity, enabling robust fibroblast adhesion and viability. This framework paves the way for tunable, ECM-mimetic dressings for chronic wound repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.